Credit Suisse (SIX:CSGN) analyst Max Yates maintained a Buy rating on Siemens Healthineers AG on Tuesday, setting a price target of EUR55, which is approximately 13.87% above the present share price of $58.2.
Yates expects Siemens Healthineers AG to post earnings per share (EPS) of $0.40 for the second quarter of 2021.
The current consensus among 9 TipRanks analysts is for a Moderate Buy rating of shares in Siemens Healthineers AG, with an average price target of $62.58.
The analysts price targets range from a high of $67.48 to a low of $55.43.
In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $3.87 billion and a net profit of $683 million. The company's market cap is $65.6 billion.
According to TipRanks.com, Credit Suisse analyst Max Yates is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 13.8% and a 84.38% success rate.
Siemens Healthineers AG operates as a holding company. The company intends to operate the digital services business. It operates through the following business segments: Imaging, Diagnotics, and Advanced Therapies. The Imaging segment offers diagnostic imaging products and a broad portfolio of advanced imaging and ultrasound systems and solutions. The Diagnostics segment offers products, services and solutions, including a broad array of testing applications, in the areas of laboratory, point of care and molecular diagnostics. The Advanced Therapies is a supplier of advanced therapy products, services and solutions to the therapy departments of healthcare providers. Siemens Healthineers was founded on December 1, 2017 and is headquartered in Erlangen, Germany.